|Bid||0.6900 x 0|
|Ask||0.7200 x 0|
|Day's range||0.6800 - 0.7200|
|52-week range||0.6600 - 2.4900|
|Beta (5Y monthly)||3.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Aurora Cannabis (NASDAQ: ACB) has been struggling for years. The stock is trading down to well under $1 per share, and another reverse stock split is inevitable for the company. Aurora Cannabis' stock price fell 96% over the past three years.
One was once a favorite among cannabis investors, but the other could become the top cannabis contender.
It's been roughly five years since Canada legalized cannabis, and it's been an unpleasant ride for investors in Aurora Cannabis (NASDAQ: ACB), one of Canada's leading growers and operators. The company became a penny stock after surging to over $120 per share in 2018. While some may hope for a tremendous comeback story, sometimes a business model just isn't good.
Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.
April 20th has a special significance for the cannabis industry. Three of those companies have especially attracted investors' attention in recent years -- Aurora Cannabis (NASDAQ: ACB), Curaleaf Holdings (OTC: CURLF), and SNDL (NASDAQ: SNDL) (formerly known as Sundial Growers). Aurora Cannabis is the worst of the group, with its share price plunging more than 80%.
Despite losing most of their value, these former Wall Street darlings have been popular buys among billionaire money managers.
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Marijuana stocks have performed poorly over the last two years. Cannabis analytics firm BDSA estimates that global cannabis sales will reach $57 billion by 2026, a 13% annual growth forecast from $30 billion in 2021, with bulk of this growth expected to be driven by the Canadian and American markets. Investment opportunities seem lucrative, and investors with a higher risk appetite might stand to profit handsomely in the long run in this volatile industry.
Canadian marijuana company Aurora Cannabis (NASDAQ: ACB) is having another bad day. The pot seller's shares were down by a noteworthy 4.34% on moderate volume as of 2:05 p.m. ET on Monday. Since the start of the year, Aurora's stock has now shed 27.5% of its value, and the share price has fallen well below the Nasdaq's $1 bid requirement, triggering a noncompliance notice from the exchange last month.
Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.
Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.
The cannabis industry in Canada hasn't been in good shape for some time. Growth is almost nonexistent, profits are elusive, and stock prices of marijuana producers have been nosediving. What's particularly telling are the moves of two of the industry's leaders, Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC).
One sector that's undoubtedly gone from bubble territory to flat-out deflated is cannabis. Many producers saw valuations skyrocket upon the federal legalization of cannabis in Canada in late 2018. U.S.-based multi-state operators (MSOs) like Curaleaf (OTC: CURLF) have certainly had a rough go over the past two years.
Suppose you bought $10,000 of Aurora Cannabis (NASDAQ: ACB) stock five years ago and held onto those shares. With that abysmal performance, you might think making a case for investing in Aurora Cannabis today would be an exercise in futility. If these four words are true, buying the heavily beaten-down marijuana stock could pay off nicely.
Aurora Cannabis (NASDAQ: ACB) is coming off a horrible 2022, in which its share price plummeted 83%. Investors might want to watch for more mergers and acquisitions, now that the business is in stronger financial shape. In Aurora Cannabis' most recent quarterly results, for the period ending Dec. 31, the company finally delivered on a long-awaited goal: reaching profitability on the basis of adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).
As the biggest recreational marijuana seller in Canada and the largest medicinal operator in the European Union, Tilray Brands (NASDAQ: TLRY) is perhaps the most globalized marijuana business in the world. If there's going to be a business that reaps the benefits of the global growth of the cannabis industry, Tilray is likely to be it. The average price-to-book (P/B) ratio of the S&P 500 is near 4, but Tilray's P/B is 0.4.
Abysmal, atrocious, horrible, rotten -- pick your favorite description for how Aurora Cannabis (NASDAQ: ACB) stock has performed over the last few years. Aurora's share price currently stands more than 99% below its level from late 2018. Aurora Cannabis has been delisted from stock exchanges before.
Canada-based Aurora Cannabis (NASDAQ: ACB) has been on a downward spiral for the past few years. Industry headwinds, as well as some of Aurora's own actions, dragged the stock down, causing investors to lose faith in the company. Aurora has left no stone unturned to achieve positive earnings before interest, taxes, depreciation, and amortization (EBITDA).
Investing in Aurora Cannabis (NASDAQ: ACB) right now would fulfill at least the latter half of that criteria, given that its shares are down by roughly 99% in the last five years. Despite its recent attempts to right the ship by getting a new CEO in 2020, slashing costs, and trying to reach profitability, the market clearly hasn't received this stock warmly, and shareholders have been retreating for quite some time now. Let's answer this question by making the strongest possible case for buying Aurora Cannabis to find out.
Aurora Cannabis (NASDAQ: ACB) hasn't been a very rewarding stock to buy in recent years. Despite the crash-and-burn stock history, there's a small body of evidence indicating that Aurora Cannabis is succeeding in making a turnaround. For investors, betting on that turnaround evolving into a bull run for the stock means believing that the company's problems will continue to abate, enabling it to reach profitability while maintaining or increasing its market share.
If Allied Market Research's estimates are correct, the global cannabis market could reach $149 billion by 2031. As with any high-growth industry, there's no doubt investing in cannabis stocks today is risky business. Let's take a closer look to see if Aurora Cannabis (NASDAQ: ACB), a once-hot cannabis stock, or Cresco Labs (OTC: CRLBF), a U.S. multi-state operator (MSO), is a better investment right now.
Nearly five years ago, Aurora Cannabis (NASDAQ: ACB) acquired medical marijuana company MedReleaf in an all-stock deal valued at roughly 3.2 billion Canadian dollars ($2.4 billion). Today, Aurora Cannabis is a small fraction of that valuation. Aurora is showing signs of progress, but is it on the right track, and will the business be in a better place a year from now?
Aurora Cannabis (NASDAQ: ACB) really, really needed some good news. Shares of the Canadian cannabis producer plunged 83% last year. And that decline came on top of a 35% drop in 2021 and a 68% plummet in 2020.